By the Numbers
Fannie Mae multifamily delinquencies hit historic high
Mary Beth Fisher, PhD | February 5, 2021
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors.
Forbearance programs, essential for many borrowers during the pandemic, have resulted in Fannie Mae multifamily delinquency rates far exceeding the peaks reached after the 2008 housing crisis. The US has recently extended federal eviction moratoriums through March 31 with many state and local jurisdictions pushing them out even further. Without an extension of the Fannie Mae and Freddie Mac forbearance program, many multifamily borrowers will likely be pushed into default. Involuntary prepayments could hurt investors in agency CMBS trading well above par with elevated levels of loans in forbearance.
The extension of the federal moratorium on evictions helps multifamily tenants. But unless that is also matched by an extension of the agency forbearance programs for multifamily property owners, the financial stress will likely translate into a greater percentage of loans currently in forbearance migrating into default. Fannie Mae recently updated their multifamily loan performance database through the third quarter of 2020. The total percentage of delinquent loans, which includes all loans in forbearance, was 1.3% as of the end of the third quarter 2020 (Exhibit 1). This far exceeded the peak of 0.8% reached during the housing crisis.
Exhibit 1: Fannie Mae multifamily delinquency rates
Agency forbearance programs, which began in April 2020, ultimately allowed multifamily borrowers to have their loans in forbearance for six months. For borrowers that entered forbearance in April, those loans were 90+ days delinquent by June 2020. The 6-month forbearance period ended September 30, with a payment on their loan due October 1. As of the end of June, nearly 1.4% of outstanding Fannie Mae multifamily loans were in forbearance and technically delinquent (Exhibit 2).
Exhibit 2: Fannie Mae multifamily total delinquencies
The good news is that by September 2020, Fannie Mae had some multifamily borrowers that began to cure their forbearance as overall delinquency rates fell slightly from 1.4% to 1.3%. The bad news is that – after reaching a trough in new delinquencies in July – a handful of new loans began to fall into delinquency or enter forbearance in August and September.
Delinquencies have increased
Since September the number of loans in forbearance has increased. As of Fannie Mae’s January 28, 2021, forbearance report, the unpaid principal balance of DUS loans in forbearance is $4.3 billion, or 1.2% of total multifamily UPB outstanding. In September, DUS loans in any stage of delinquency totaled $3.6 billion, or 1.0% of total Fannie Mae multifamily loans outstanding. Overall, the percentage of Fannie Mae’s multifamily UPB that is currently in some stage of delinquency has likely increased from 1.3% in September 2020 to 1.5% by January 2021. This is also consistent with delinquency and forbearance trends in Freddie Mac and Ginnie Mae multifamily programs.
Involuntary prepayments could hurt performance
The issue for agency CMBS investors is obviously not one of credit, but the potential for loans in delinquency and forbearance to roll over into default. High dollar priced securities can underperform when a significant amount of principal is repaid without penalty. If agency multifamily forbearance programs are not extended to match the extension in tenant forbearance, a much larger percentage of currently delinquent loans could enter workout. The return of principal in high dollar price agency CMBS will lower total returns.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of Amherst Pierpont’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, Amherst Pierpont may act as a market maker or principal dealer, and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://apsec.com/disclaimers.
Copyright ©2022 Amherst Pierpont Securities LLC and its affiliates (“Amherst Pierpont”). All rights reserved. Amherst Pierpont Securities LLC is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, Amherst Pierpont (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which Amherst Pierpont has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of Amherst Pierpont’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, Amherst Pierpont or any of its affiliates may act as a market maker or principal dealer, and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by Amherst Pierpont, (iv) should not be reproduced or disclosed to any other person, without Amherst Pierpont’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, Amherst Pierpont (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.